10 Low Risk High Reward Stocks Set to Triple by 2030

3. aTyr Pharma, Inc. (NASDAQ:ATYR)

Number of Hedge Fund Holders: 25

Potential upside: 415.95%

aTyr Pharma, Inc. (NASDAQ:ATYR) is a clinical-stage biotech company working on breakthrough medicines using its special tRNA synthetase platform. Its main drug, efzofitimod, is being tested for pulmonary sarcoidosis – a rare, long-lasting disease without many treatment options. The company is also developing other drugs for systemic sclerosis, lung disease, and similar fibrosis conditions.

The company ended 2024 with $75.1 million in cash and raised $18.8 million in early 2025 through ATM offerings, which should keep it funded until Q1 2026. This money supports aTyr’s ongoing clinical trials, including the major Phase 3 EFZO-FIT study and Phase 2 EFZO-CONNECT study. In 2024, aTyr Pharma, Inc. (NASDAQ:ATYR) spent $54.4 million on R&D, consisting mostly of these trials and manufacturing efzofitimod.

Moreover, the company just finished enrolling patients in its Phase 3 EFZO-FIT study – the biggest intervention trial ever done for pulmonary sarcoidosis. aTyr Pharma, Inc. (NASDAQ:ATYR) is also running a Phase 2 trial for systemic sclerosis lung disease and has published lab research showing how efzofitimod affects lung inflammation and scarring.

With solid funding, promising data, and several drug candidates, aTyr Pharma, Inc. (NASDAQ:ATYR) looks like one of the best low risk stocks out there.